Mylan agrees to buy Famy Care Businesses
The acquisition will build on Mylan’s existing partnerships with Famy Care in North America, Europe and Australia, and provide Mylan with an enhanced and now vertically integrated platform
Health innovation platform developer Aditxt and its fully owned subsidiary Ignite Proteomics have announced their plans for a business combination with a strategic partner that values the latter at an implied equity value of nearly $150m.
The cell bank contains over 2.6 billion human cells, sufficient to meet the company’s foreseeable clinical trial requirements. "Completing the production of clinical-grade cells using the previously published
Following a meeting with its CBD Initiative Scientific/Medical Advisory Board last November, the company has marked significant progress in readying its first natural CBD-based nutraceutical supplement for introduction
The drug is approved in combination with letrozole, to treat postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer as initial endocrine-based